By Fineline Cube Hisun Pharmaceutical (SHA: 600267) announced it has entered into an exclusive licensing agreement with EnliTISA (Shanghai) Pharmaceutical Co., Ltd. for the development, registration, manufacturing, and commercialization rights of the systemically administered formulation of TISA-818, a Class 1 innovative chemical drug, across Mainland China, Hong Kong, and Macao.
Deal Structure & Financial Terms
| Component | Detail |
|---|---|
| Upfront Payment | RMB 45 million |
| Refund Clause | Partial or full refund available if NMPA conclusions on clinical endpoints/patient populations deviate from expectations |
| Development Milestones | Up to RMB 100 million |
| Approval & New Indication Milestones | Additional RMB 100 million |
| Commercial Royalties | Tiered royalties based on annual net sales |
Under the agreement, Hisun will serve as the exclusive licensee and Marketing Authorization Holder (MAH) for TISA-818 in the designated region.
Drug Profile & Mechanism of Action
- Molecule: TISA-818 – Class 1 innovative chemical drug
- Mechanism: Novel multi-target immunomodulator that regulates immune responses through multiple pathways
- Key Differentiator: Provides anti-inflammatory effects without causing immunosuppression
- Development Status:
- Completed Phase I clinical trial for pulmonary fibrosis in Europe
- Completed Phase IIa clinical trial for Acute Respiratory Distress Syndrome (ARDS) in China
- Clinical Potential: Data demonstrate strong therapeutic potential specifically for ARDS treatment
Strategic Rationale & Market Opportunity
- Unmet Medical Need: ARDS has limited treatment options with high mortality rates (30-40%)
- Market Size: China reports approximately 200,000 ARDS cases annually, with growing incidence
- Competitive Landscape: Few novel mechanisms targeting ARDS inflammation without immunosuppression
- Pipeline Expansion: Hisun gains rights to pursue additional indications beyond current focus areas
- Risk Mitigation: Refund clause provides protection against regulatory uncertainty
Hisun’s acquisition of TISA-818 aligns with its strategy to expand its portfolio of innovative therapeutics in high-need respiratory and inflammatory conditions. The company expects to file for marketing authorization following completion of additional clinical development activities.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for TISA-818. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and market dynamics.-Fineline Info & Tech